Clinical trial NCT01810861: Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
Official title: SEROTYPE DISTRIBUTION AND ANTIBIOTIC SUSCEPTIBILITY OF STREPTOCOCCUS PNEUMONIAE CAUSING INVASIVE DISEASES IN CHILDREN AND ADULTS: A LABORATORY- BASED MULTICENTER RETROSPECTIVE STUDY
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumococcal Diseases
Keywords: serotype distribution
streptococcus pneumoniae
pneumonia
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-03-14
Enrollment: 922
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pneumococcal isolates that are obtained from the blood, CSF and/or other sterile body areas (catheter, pleural fluid, parasynthesis fluid, pericardial fluid, synovial fluid, BAL) with the aim of routine laboratory diagnosis from the pediatric patients that are younger than 18 years old (≤18), who are accepted to the pediatric clinic with the diagnosis of meningitides, bacteremia - sepsis or pneumonia, will be included in the trial.

S.pneumoniae isolates that meet the inclusion criteria and that are obtained from the invasive clinical samples of the adult patients that are over 18 years old (\>18) and applied to the hospital are included in the trial.

Brief summary: The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.

Detailed description: Non-interventional observational study Descriptive analysis will be conducted.

Eligibility criteria: Inclusion Criteria:

Serotype distribution and antibiotic sensitivity of pneumococcal isolates that causes invasive pneumococcal diseases which are obtained from the blood, CSF, and/or all other sterile body areas (catheter, pleural fluid, parasynthesis fluid, pericardial fluid, synovial fluid, BAL) of the adults of 18 years of age or older with children that are younger than 18 years old at these centers and laboratories will be defined.

Exclusion Criteria:

Isolation of any other microorganism than pneumococcus at the same sample.

Primary outcomes:
measure: Identification of S. pneumoniae serotype distribution
timeFrame: 4 years
Secondary outcomes:
measure: Identification of antibiotic susceptibility of the isolates
timeFrame: 4 years
Other outcomes:
Locations:
city: Balcova
country: Turkey
facility: Dokuz Eylul University Medical Faculty, Department of Chest Diseases
state: Izmir
city: Gaziantep
country: Turkey
facility: Gaziantep Universitesi Tip Fakultesi Mikrobiyoloji
state: Turkiye
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Istanbul Tip Fakultesi Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dali
state: Turkiye
city: Adana
country: Turkey
facility: Cukurova Universitesi Tip Fakultesi Tibbi Mikrobiyoloji Anabilim Dali
city: Ankara / Altındağ
country: Turkey
facility: Ankara Yüksek İhtisas Eğitim ve Araştırma Hastanesi Kardiyoloji Kliniği
city: Ankara
country: Turkey
facility: Hacettepe Universitesi Tip Fakultesi Cocuk Enfeksiyon Hastaliklari Bilim Dali
city: Ankara
country: Turkey
facility: Ankara Meslek Hastalıkları Hastanesi
city: Ankara
country: Turkey
facility: Sami Ulus Kadin Dogum Cocuk Sagligi ve Hastaliklari Egitim Arastirma Hastanesi
city: Antalya
country: Turkey
facility: Antalya Egitim ve Arastirma Hastanesi Tibbi Mikrobiyoloji
city: Antalya
country: Turkey
facility: Akdeniz University Medical Faculty Microbiology Department
city: Antalya
country: Turkey
facility: Akdeniz University Medical Faculty, Microbiology
city: Atakum Samsun
country: Turkey
facility: Samsun Ondokuz Mayis Universitesi Tibbi Mikrobiyoloji ABD
city: Bursa
country: Turkey
facility: Uludag Universitesi Tip Fakultesi Mikrobiyoloji ve Enfeksiyon Hastaliklari Anabilim Dali
city: Diyarbakir
country: Turkey
facility: Diyarbakir Dicle Universitesi Tibbi Mikrobiyoloji ABD
city: Diyarbakir
country: Turkey
facility: Dicle Universitesi Tip Fakultesi Tibbi Mikrobiyoloji Anabilim Dali
city: Elazig
country: Turkey
facility: Firat Universitesi Tip Fakultesi Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dali
city: Eskisehir
country: Turkey
facility: Osmangazi University Medical Faculty, Microbiology
city: Istanbul
country: Turkey
facility: Marmara Universitesi Tip Fakultesi
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Cerrahpasa Tip Fakultesi Cocuk Sagligi ve Hastaliklari Ana Bilim Dali
city: Izmir
country: Turkey
facility: Ege University Medical Faculty, Microbiology
city: İzmir
country: Turkey
facility: İzmir Tepecik Rearch and Training Hospital
city: Kagithane Istanbul
country: Turkey
facility: Istanbul Okmeydani Egitim ve Arastirma Hastanesi Kagithane Semt Poliklinii
city: Kahramanmaras
country: Turkey
facility: Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Tibbi Mikrobiyoloji Anabilim Dali
city: Kayseri
country: Turkey
facility: Erciyes University Medical Faculty
city: Kayseri
country: Turkey
facility: Kayseri Training and Research Hospital
city: Konak Izmir
country: Turkey
facility: Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
city: Konya
country: Turkey
facility: Necmettin Erbakan University Meram Faculty of Medicine Deparment of Pediatrics
city: Mersin
country: Turkey
facility: Mersin University Medical Faculty, Microbiology
city: Samanpazari, Ankara
country: Turkey
facility: Hacettepe University Medical Faculty Hospital
city: Selcuklu /konya
country: Turkey
facility: Selcuk Universitesi Tip Fakultesi Dahili Tip Bilimleri Bolumu Cocuk Sagligi ve Hastaliklari A.B.D
city: Trabzon
country: Turkey
facility: Karadeniz Teknik Universitesi Tip Fakultesi Tibbi Mikrobiyoloji Anabilim Dali
city: Van
country: Turkey
facility: Van 100.Yl University Medical Faculty
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: